Business (Details) $ in Thousands |
1 Months Ended | 3 Months Ended | |||
|---|---|---|---|---|---|
|
Jun. 11, 2020
USD ($)
shares
|
Jan. 31, 2021
USD ($)
shares
|
Mar. 31, 2021
USD ($)
product
|
Mar. 31, 2020
USD ($)
|
Dec. 31, 2020
USD ($)
|
|
| Subsequent Event [Line Items] | |||||
| Sale of stock (in shares) | shares | 13,971,889 | ||||
| Cash and cash equivalents | $ 38,292 | $ 5,659 | $ 18,919 | ||
| Net loss | (30,680) | (21,117) | |||
| Net cash used in operating activities | (18,316) | $ (5,739) | |||
| (Accumulated deficit) retained earnings | $ (208,470) | $ (177,790) | |||
| Warrant | |||||
| Subsequent Event [Line Items] | |||||
| Sale of stock (in shares) | shares | 1,676,923 | ||||
| Underwritten Public Offering | |||||
| Subsequent Event [Line Items] | |||||
| Sale of stock (in shares) | shares | 15,180,000 | 13,971,889 | |||
| Net proceeds | $ 35,400 | $ 37,700 | |||
| Neurological Clinical And Preclinical Stage Compounds | |||||
| Subsequent Event [Line Items] | |||||
| Number of products in development | product | 2 | ||||
| Clinical Stage | |||||
| Subsequent Event [Line Items] | |||||
| Number of products in development | product | 4 | ||||
| X | ||||||||||
- Definition Number of Products Developed No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash received on stock transaction after deduction of issuance costs. No definition available.
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|